Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Author(s) -
Ole Frøbert,
Matthias Götberg,
David Erlinge,
Zubair Akhtar,
Evald Høj Christiansen,
C. Raina MacIntyre,
Keith G. Oldroyd,
Zuzana Moťovská,
Andrejs Ērglis,
Rasmus Moer,
Ota Hlinomaz,
Lars Jakobsen,
Thomas Engstrøm,
Lisette Okkels Jensen,
Christian Oliver Fallesen,
Svend Eggert Jensen,
Oskar Angerås,
Fredrik Calais,
Amra Kåregren,
Jörg Lauermann,
Arash Mokhtari,
Johan Nilsson,
Jonas Persson,
Per Stalby,
Abu K.M.M. Islam,
Afzalur Rahman,
FazilaTunNesa Malik,
Sohel Reza Choudhury,
Timothy Collier,
Stuart J. Pocock,
John Pernow
Publication year - 2021
Publication title -
circulation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.121.057042
Subject(s) - medicine , hazard ratio , myocardial infarction , placebo , randomized controlled trial , influenza vaccine , clinical endpoint , cause of death , vaccination , disease , immunology , confidence interval , pathology , alternative medicine
Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom